

# New Hampshire Medicaid Fee-for-Service Program

## GLP-1 Receptor Agonist Criteria

Approval Date: January 22, 2024

### Medications

Brand Name	Generic Name	Indication
<b>Trulicity®</b>	dulaglutide	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥ 10 years of age with T2DM</li> <li>Reduce the risk of major adverse cardiovascular events (MACE) in adults with T2DM who have established CVD or multiple cardiovascular risk factors</li> </ul>
<b>Byetta®</b>	exenatide	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults with T2DM who are taking metformin, a sulfonylurea (SU), thiazolidinedione (TZD), or a combination of metformin and an SU or TZD but have not achieved adequate glycemic control</li> <li>Add-on therapy to insulin glargine, with or without metformin and/or a TZD, in conjunction with diet and exercise for adults with T2DM who are not achieving adequate glycemic control on insulin glargine alone</li> </ul>
<b>Bydureon BCise®</b>	exenatide ER	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥ 10 years of age with T2DM</li> </ul>
<b>Victoza®</b>	liraglutide	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adult and pediatric patients ≥ 10 years of age with T2DM</li> <li>Reduce the risk of MACE in adults with T2DM and established CVD</li> </ul>
<b>Xultophy®</b>	liraglutide/insulin degludec	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults with T2DM</li> </ul>
<b>Soliqua®</b>	lixisenatide/insulin glargine	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults with T2DM</li> </ul>
<b>Ozempic®</b>	semaglutide	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults with T2DM</li> <li>To reduce the risk of MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with T2DM and established CVD</li> </ul>
<b>Rybelsus®</b>	semaglutide	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults with T2DM</li> </ul>
<b>Mounjaro™</b>	tirzepatide	<ul style="list-style-type: none"> <li>Adjunct to diet and exercise to improve glycemic control in adults with T2DM</li> </ul>

Proprietary & Confidential

© 2009–2024 Magellan Rx Management. All rights reserved.

Magellan Medicaid Administration is a division of Magellan Rx Management, LLC.

## Criteria for Approval

1. Patient has a diagnosis of a type 2 diabetes mellitus; **AND**
2. Patient age is supported by FDA-approved indication; **AND**
3. Medication requested will be used as an adjunct to diet and exercise; **AND**
4. Patient has had a trial of an oral antihyperglycemic.

## Criteria for Denial

Criteria for approval are not met.

**Length of Approval:** One year

**Non-preferred drugs on the Preferred Drug List (PDL) require additional prior authorization.**

## Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	12/08/2023
Commissioner Designee	Approval	01/22/2024